Navigation Links
Dendreon to Host Conference Call on August 3, 2011 to Announce Second Quarter 2011 Financial Results
Date:7/8/2011

SEATTLE, July 8, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Wednesday, August 3, 2011 at 4:30 p.m. ET to review the second quarter 2011 financial results.  Access to the discussion may be obtained as follows: Time:

4:30 PM ET / 1:30 PM PTDate:

August 3, 2011Dial-in:

1- 877-548-9590 (domestic) or +1-720-545-0037 (international);conference pass code: 82447836Webcast:

www.dendreon.com (homepage and investor relations section) A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-642-1687 or +1-706-645-9291 for international callers; the conference ID number is 82447836. The replay will be available from 7:30 pm ET on August 3 until 11:59 pm ET on August 10.  In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.About DendreonDendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010.  Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
2. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility
3. Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program
4. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
5. Dendreon Announces Webcast Presentation at Upcoming Conferences
6. Dendreon Reports First Quarter 2011 Financial Results
7. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
8. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
9. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
10. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
11. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, provider ... has signed a collaborative and sponsored research agreement ... Silvia Muro . The overall goal of the ... of various 3DNA designs and formulations after ... diseases of the vasculature as well as inflammatory ...
(Date:4/25/2017)... 25, 2017 Providence ... its novel immune-modulating technology to an undisclosed global pharmaceutical ... Tregitopes, pronounced T·rej·itopes, are a set ... EpiVax CEO Annie De Groot and ... G, an autoimmune disease therapy, Tregitopes are capable ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... in a cellular milieu; however, the broad application of this cellular target engagement ... with sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for particular ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of ... round funding to three startups through the UConn Innovation Fund. The $1.5 million ... startups affiliated with UConn. , The UConn Innovation Fund provides investments of up ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):